APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brain Disease Modalities And Software

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Brain Disease Modalities And Software Market Analysis and Forecast 2026-2032

5 March 2026202 pages

Choose your research edition.

Industry ResearchBrain Disease Modalities And Software Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Brain Disease Modalities And Software Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Brain Disease Modalities And Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brain Disease Modalities And Software Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Brain Disease Modalities And Software Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Brain Disease Modalities And Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Brain Disease Modalities And Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Brain Disease Modalities And Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Brain Disease Modalities And Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Brain Disease Modalities And Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Brain Disease Modalities And Software include Quantib, Brainomix, General Electric, Imaging Biometrics, United Imaging Healthcare Co, Siemens, Healthineers AG, Koninklijke Philips N.V. and Canon, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Brain Disease Modalities And Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Brain Disease Modalities And Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Brain Disease Modalities And Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Brain Disease Modalities And Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Brain Disease Modalities And Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Brain Disease Modalities And Software revenue, projected growth trends, production technology, application and end-user industry.

Brain Disease Modalities And Software Segment by Company

Quantib

Brainomix

General Electric

Imaging Biometrics

United Imaging Healthcare Co

Siemens

Healthineers AG

Koninklijke Philips N.V.

Canon

Vuno

Aspect Imaging

IXICO

QMENTA

I. Analysis

Fujifilm Holdings

Other Prominent Players

Brain Disease Modalities And Software Segment by Type

Brain Imaging Modalities

Brain Analysis Software

Brain Disease Modalities And Software Segment by Application

Adults

Pediatrics and Infants

Brain Disease Modalities And Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brain Disease Modalities And Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brain Disease Modalities And Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brain Disease Modalities And Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Brain Disease Modalities And Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Brain Disease Modalities And Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Brain Disease Modalities And Software revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Brain Disease Modalities And Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Brain Imaging Modalities Major Player Table 3. Brain Analysis Software Major Player Table 4. Global Brain Disease Modalities And Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adults Major Player Table 6. Pediatrics and Infants Major Player Table 7. Brain Disease Modalities And Software Industry Trends Table 8. Brain Disease Modalities And Software Industry Drivers Table 9. Brain Disease Modalities And Software Industry Opportunities and Challenges Table 10. Brain Disease Modalities And Software Industry Restraints Table 11. Global Brain Disease Modalities And Software Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Brain Disease Modalities And Software Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Brain Disease Modalities And Software Market Share by Region (2021-2026) Table 14. Global Brain Disease Modalities And Software Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Brain Disease Modalities And Software Market Share by Region (2027-2032) Table 16. Global Brain Disease Modalities And Software Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Brain Disease Modalities And Software Revenue Market Share by Players (2021-2026) Table 18. Global Brain Disease Modalities And Software Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Brain Disease Modalities And Software Key Players Headquarters & Area Served Table 20. Global Brain Disease Modalities And Software Players, Product Type & Application Table 21. Global Brain Disease Modalities And Software Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Brain Disease Modalities And Software by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Brain Disease Modalities And Software Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Brain Disease Modalities And Software Revenue Market Share by Type (2021-2026) Table 28. Global Brain Disease Modalities And Software Revenue Market Share by Type (2027-2032) Table 29. Global Brain Disease Modalities And Software Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Brain Disease Modalities And Software Revenue Market Share by Application (2021-2026) Table 33. Global Brain Disease Modalities And Software Revenue Market Share by Application (2027-2032) Table 34. Quantib Company Information Table 35. Quantib Business Overview Table 36. Quantib Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Quantib Brain Disease Modalities And Software Product Portfolio Table 38. Quantib Recent Development Table 39. Brainomix Company Information Table 40. Brainomix Business Overview Table 41. Brainomix Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Brainomix Brain Disease Modalities And Software Product Portfolio Table 43. Brainomix Recent Development Table 44. General Electric Company Information Table 45. General Electric Business Overview Table 46. General Electric Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. General Electric Brain Disease Modalities And Software Product Portfolio Table 48. General Electric Recent Development Table 49. Imaging Biometrics Company Information Table 50. Imaging Biometrics Business Overview Table 51. Imaging Biometrics Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Imaging Biometrics Brain Disease Modalities And Software Product Portfolio Table 53. Imaging Biometrics Recent Development Table 54. United Imaging Healthcare Co Company Information Table 55. United Imaging Healthcare Co Business Overview Table 56. United Imaging Healthcare Co Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. United Imaging Healthcare Co Brain Disease Modalities And Software Product Portfolio Table 58. United Imaging Healthcare Co Recent Development Table 59. Siemens Company Information Table 60. Siemens Business Overview Table 61. Siemens Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Siemens Brain Disease Modalities And Software Product Portfolio Table 63. Siemens Recent Development Table 64. Healthineers AG Company Information Table 65. Healthineers AG Business Overview Table 66. Healthineers AG Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Healthineers AG Brain Disease Modalities And Software Product Portfolio Table 68. Healthineers AG Recent Development Table 69. Koninklijke Philips N.V. Company Information Table 70. Koninklijke Philips N.V. Business Overview Table 71. Koninklijke Philips N.V. Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Koninklijke Philips N.V. Brain Disease Modalities And Software Product Portfolio Table 73. Koninklijke Philips N.V. Recent Development Table 74. Canon Company Information Table 75. Canon Business Overview Table 76. Canon Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Canon Brain Disease Modalities And Software Product Portfolio Table 78. Canon Recent Development Table 79. Vuno Company Information Table 80. Vuno Business Overview Table 81. Vuno Brain Disease Modalities And Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Vuno Brain Disease Modalities And Software Product Portfolio Table 83. Vuno Recent Development Table 84. Aspect Imaging Company Information Table 85. Aspect Imaging Business Overview Table 86. Aspect Imaging Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Aspect Imaging Brain Disease Modalities And Software Product Portfolio Table 88. Aspect Imaging Recent Development Table 89. IXICO Company Information Table 90. IXICO Business Overview Table 91. IXICO Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. IXICO Brain Disease Modalities And Software Product Portfolio Table 93. IXICO Recent Development Table 94. QMENTA Company Information Table 95. QMENTA Business Overview Table 96. QMENTA Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. QMENTA Brain Disease Modalities And Software Product Portfolio Table 98. QMENTA Recent Development Table 99. I. Analysis Company Information Table 100. I. Analysis Business Overview Table 101. I. Analysis Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. I. Analysis Brain Disease Modalities And Software Product Portfolio Table 103. I. Analysis Recent Development Table 104. Fujifilm Holdings Company Information Table 105. Fujifilm Holdings Business Overview Table 106. Fujifilm Holdings Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Fujifilm Holdings Brain Disease Modalities And Software Product Portfolio Table 108. Fujifilm Holdings Recent Development Table 109. Other Prominent Players Company Information Table 110. Other Prominent Players Business Overview Table 111. Other Prominent Players Brain Disease Modalities And Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Other Prominent Players Brain Disease Modalities And Software Product Portfolio Table 113. Other Prominent Players Recent Development Table 114. North America Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Brain Disease Modalities And Software Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Brain Disease Modalities And Software Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Brain Disease Modalities And Software Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Brain Disease Modalities And Software Revenue by Country (US$ Million) & (2027-2032) Table 128. China Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 129. China Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 130. China Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 131. China Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Brain Disease Modalities And Software Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Brain Disease Modalities And Software Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Brain Disease Modalities And Software Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Brain Disease Modalities And Software Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Brain Disease Modalities And Software Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Brain Disease Modalities And Software Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Brain Disease Modalities And Software Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Brain Disease Modalities And Software Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Brain Disease Modalities And Software Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Brain Disease Modalities And Software Image Figure 2. Global Brain Disease Modalities And Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Brain Disease Modalities And Software Market Size Share 2021 VS 2025 VS 2032 Figure 4. Brain Imaging Modalities Image Figure 5. Brain Analysis Software Image Figure 6. Global Brain Disease Modalities And Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Brain Disease Modalities And Software Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adults Image Figure 9. Pediatrics and Infants Image Figure 10. Global Brain Disease Modalities And Software Market Size (US$ Million) & (2021-2032) Figure 11. Global Brain Disease Modalities And Software Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Brain Disease Modalities And Software Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Brain Disease Modalities And Software Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Brain Disease Modalities And Software Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Brain Disease Modalities And Software Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Brain Disease Modalities And Software Revenue Market Share by Type (2021-2032) Figure 18. Global Brain Disease Modalities And Software Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Brain Disease Modalities And Software Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Brain Disease Modalities And Software Revenue Market Share by Application (2021-2032) Figure 21. North America Brain Disease Modalities And Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Brain Disease Modalities And Software Revenue Share by Type (2021-2032) Figure 23. North America Brain Disease Modalities And Software Revenue Share by Application (2021-2032) Figure 24. North America Brain Disease Modalities And Software Revenue Share by Country (2021-2032) Figure 25. United States Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Brain Disease Modalities And Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Brain Disease Modalities And Software Revenue Share by Type (2021-2032) Figure 30. Europe Brain Disease Modalities And Software Revenue Share by Application (2021-2032) Figure 31. Europe Brain Disease Modalities And Software Revenue Share by Country (2021-2032) Figure 32. Germany Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Brain Disease Modalities And Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Brain Disease Modalities And Software Revenue Share by Type (2021-2032) Figure 42. China Brain Disease Modalities And Software Revenue Share by Application (2021-2032) Figure 43. Asia Brain Disease Modalities And Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Brain Disease Modalities And Software Revenue Share by Type (2021-2032) Figure 45. Asia Brain Disease Modalities And Software Revenue Share by Application (2021-2032) Figure 46. Asia Brain Disease Modalities And Software Revenue Share by Region (2021-2032) Figure 47. Japan Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Brain Disease Modalities And Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Brain Disease Modalities And Software Revenue Share by Type (2021-2032) Figure 55. SAMEA Brain Disease Modalities And Software Revenue Share by Application (2021-2032) Figure 56. SAMEA Brain Disease Modalities And Software Revenue Share by Country (2021-2032) Figure 57. Brazil Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Brain Disease Modalities And Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Brain Imaging Modalities
  • Brain Analysis Software
Applications
  • Adults
  • Pediatrics and Infants
Companies covered
  • Quantib
  • Brainomix
  • General Electric
  • Imaging Biometrics
  • United Imaging Healthcare Co
  • Siemens
  • Healthineers AG
  • Koninklijke Philips N.V.
  • Canon
  • Vuno
  • Aspect Imaging
  • IXICO
  • QMENTA
  • I. Analysis
  • Fujifilm Holdings
  • Other Prominent Players

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Brain Disease Modalities And Software Market by Type
  3. 1.2.1 Global Brain Disease Modalities And Software Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Brain Imaging Modalities
  5. 1.2.3 Brain Analysis Software
  6. 1.3 Brain Disease Modalities And Software Market by Application
  7. 1.3.1 Global Brain Disease Modalities And Software Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adults
  9. 1.3.3 Pediatrics and Infants
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Brain Disease Modalities And Software Market Dynamics
  1. 2.1 Brain Disease Modalities And Software Industry Trends
  2. 2.2 Brain Disease Modalities And Software Industry Drivers
  3. 2.3 Brain Disease Modalities And Software Industry Opportunities and Challenges
  4. 2.4 Brain Disease Modalities And Software Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Brain Disease Modalities And Software Market Perspective (2021-2032)
  2. 3.2 Global Brain Disease Modalities And Software Growth Trends by Region
  3. 3.2.1 Global Brain Disease Modalities And Software Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Brain Disease Modalities And Software Market Size by Region (2021-2026)
  5. 3.2.3 Global Brain Disease Modalities And Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Brain Disease Modalities And Software Revenue by Players
  2. 4.1.1 Global Brain Disease Modalities And Software Revenue by Players (2021-2026)
  3. 4.1.2 Global Brain Disease Modalities And Software Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Brain Disease Modalities And Software Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Brain Disease Modalities And Software Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Brain Disease Modalities And Software Key Players Headquarters & Area Served
  7. 4.4 Global Brain Disease Modalities And Software Players, Product Type & Application
  8. 4.5 Global Brain Disease Modalities And Software Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Brain Disease Modalities And Software Market CR5 and HHI
  11. 4.6.3 2025 Brain Disease Modalities And Software Tier 1, Tier 2, and Tier 3
5 Brain Disease Modalities And Software Market Size by Type
  1. 5.1 Global Brain Disease Modalities And Software Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 5.3 Global Brain Disease Modalities And Software Revenue Market Share by Type (2021-2032)
6 Brain Disease Modalities And Software Market Size by Application
  1. 6.1 Global Brain Disease Modalities And Software Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Brain Disease Modalities And Software Revenue by Application (2021-2032)
  3. 6.3 Global Brain Disease Modalities And Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Quantib
  2. 7.1.1 Quantib Company Information
  3. 7.1.2 Quantib Business Overview
  4. 7.1.3 Quantib Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Quantib Brain Disease Modalities And Software Product Portfolio
  6. 7.1.5 Quantib Recent Developments
  7. 7.2 Brainomix
  8. 7.2.1 Brainomix Company Information
  9. 7.2.2 Brainomix Business Overview
  10. 7.2.3 Brainomix Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Brainomix Brain Disease Modalities And Software Product Portfolio
  12. 7.2.5 Brainomix Recent Developments
  13. 7.3 General Electric
  14. 7.3.1 General Electric Company Information
  15. 7.3.2 General Electric Business Overview
  16. 7.3.3 General Electric Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  17. 7.3.4 General Electric Brain Disease Modalities And Software Product Portfolio
  18. 7.3.5 General Electric Recent Developments
  19. 7.4 Imaging Biometrics
  20. 7.4.1 Imaging Biometrics Company Information
  21. 7.4.2 Imaging Biometrics Business Overview
  22. 7.4.3 Imaging Biometrics Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Imaging Biometrics Brain Disease Modalities And Software Product Portfolio
  24. 7.4.5 Imaging Biometrics Recent Developments
  25. 7.5 United Imaging Healthcare Co
  26. 7.5.1 United Imaging Healthcare Co Company Information
  27. 7.5.2 United Imaging Healthcare Co Business Overview
  28. 7.5.3 United Imaging Healthcare Co Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  29. 7.5.4 United Imaging Healthcare Co Brain Disease Modalities And Software Product Portfolio
  30. 7.5.5 United Imaging Healthcare Co Recent Developments
  31. 7.6 Siemens
  32. 7.6.1 Siemens Company Information
  33. 7.6.2 Siemens Business Overview
  34. 7.6.3 Siemens Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Siemens Brain Disease Modalities And Software Product Portfolio
  36. 7.6.5 Siemens Recent Developments
  37. 7.7 Healthineers AG
  38. 7.7.1 Healthineers AG Company Information
  39. 7.7.2 Healthineers AG Business Overview
  40. 7.7.3 Healthineers AG Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Healthineers AG Brain Disease Modalities And Software Product Portfolio
  42. 7.7.5 Healthineers AG Recent Developments
  43. 7.8 Koninklijke Philips N.V.
  44. 7.8.1 Koninklijke Philips N.V. Company Information
  45. 7.8.2 Koninklijke Philips N.V. Business Overview
  46. 7.8.3 Koninklijke Philips N.V. Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Koninklijke Philips N.V. Brain Disease Modalities And Software Product Portfolio
  48. 7.8.5 Koninklijke Philips N.V. Recent Developments
  49. 7.9 Canon
  50. 7.9.1 Canon Company Information
  51. 7.9.2 Canon Business Overview
  52. 7.9.3 Canon Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Canon Brain Disease Modalities And Software Product Portfolio
  54. 7.9.5 Canon Recent Developments
  55. 7.10 Vuno
  56. 7.10.1 Vuno Company Information
  57. 7.10.2 Vuno Business Overview
  58. 7.10.3 Vuno Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Vuno Brain Disease Modalities And Software Product Portfolio
  60. 7.10.5 Vuno Recent Developments
  61. 7.11 Aspect Imaging
  62. 7.11.1 Aspect Imaging Company Information
  63. 7.11.2 Aspect Imaging Business Overview
  64. 7.11.3 Aspect Imaging Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Aspect Imaging Brain Disease Modalities And Software Product Portfolio
  66. 7.11.5 Aspect Imaging Recent Developments
  67. 7.12 IXICO
  68. 7.12.1 IXICO Company Information
  69. 7.12.2 IXICO Business Overview
  70. 7.12.3 IXICO Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  71. 7.12.4 IXICO Brain Disease Modalities And Software Product Portfolio
  72. 7.12.5 IXICO Recent Developments
  73. 7.13 QMENTA
  74. 7.13.1 QMENTA Company Information
  75. 7.13.2 QMENTA Business Overview
  76. 7.13.3 QMENTA Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  77. 7.13.4 QMENTA Brain Disease Modalities And Software Product Portfolio
  78. 7.13.5 QMENTA Recent Developments
  79. 7.14 I. Analysis
  80. 7.14.1 I. Analysis Company Information
  81. 7.14.2 I. Analysis Business Overview
  82. 7.14.3 I. Analysis Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  83. 7.14.4 I. Analysis Brain Disease Modalities And Software Product Portfolio
  84. 7.14.5 I. Analysis Recent Developments
  85. 7.15 Fujifilm Holdings
  86. 7.15.1 Fujifilm Holdings Company Information
  87. 7.15.2 Fujifilm Holdings Business Overview
  88. 7.15.3 Fujifilm Holdings Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Fujifilm Holdings Brain Disease Modalities And Software Product Portfolio
  90. 7.15.5 Fujifilm Holdings Recent Developments
  91. 7.16 Other Prominent Players
  92. 7.16.1 Other Prominent Players Company Information
  93. 7.16.2 Other Prominent Players Business Overview
  94. 7.16.3 Other Prominent Players Brain Disease Modalities And Software Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Other Prominent Players Brain Disease Modalities And Software Product Portfolio
  96. 7.16.5 Other Prominent Players Recent Developments
8 North America
  1. 8.1 North America Brain Disease Modalities And Software Revenue (2021-2032)
  2. 8.2 North America Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 8.2.1 North America Brain Disease Modalities And Software Revenue by Type (2021-2026)
  4. 8.2.2 North America Brain Disease Modalities And Software Revenue by Type (2027-2032)
  5. 8.3 North America Brain Disease Modalities And Software Revenue Share by Type (2021-2032)
  6. 8.4 North America Brain Disease Modalities And Software Revenue by Application (2021-2032)
  7. 8.4.1 North America Brain Disease Modalities And Software Revenue by Application (2021-2026)
  8. 8.4.2 North America Brain Disease Modalities And Software Revenue by Application (2027-2032)
  9. 8.5 North America Brain Disease Modalities And Software Revenue Share by Application (2021-2032)
  10. 8.6 North America Brain Disease Modalities And Software Revenue by Country
  11. 8.6.1 North America Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Brain Disease Modalities And Software Revenue by Country (2021-2026)
  13. 8.6.3 North America Brain Disease Modalities And Software Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Brain Disease Modalities And Software Revenue (2021-2032)
  2. 9.2 Europe Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 9.2.1 Europe Brain Disease Modalities And Software Revenue by Type (2021-2026)
  4. 9.2.2 Europe Brain Disease Modalities And Software Revenue by Type (2027-2032)
  5. 9.3 Europe Brain Disease Modalities And Software Revenue Share by Type (2021-2032)
  6. 9.4 Europe Brain Disease Modalities And Software Revenue by Application (2021-2032)
  7. 9.4.1 Europe Brain Disease Modalities And Software Revenue by Application (2021-2026)
  8. 9.4.2 Europe Brain Disease Modalities And Software Revenue by Application (2027-2032)
  9. 9.5 Europe Brain Disease Modalities And Software Revenue Share by Application (2021-2032)
  10. 9.6 Europe Brain Disease Modalities And Software Revenue by Country
  11. 9.6.1 Europe Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Brain Disease Modalities And Software Revenue by Country (2021-2026)
  13. 9.6.3 Europe Brain Disease Modalities And Software Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Brain Disease Modalities And Software Revenue (2021-2032)
  2. 10.2 China Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 10.2.1 China Brain Disease Modalities And Software Revenue by Type (2021-2026)
  4. 10.2.2 China Brain Disease Modalities And Software Revenue by Type (2027-2032)
  5. 10.3 China Brain Disease Modalities And Software Revenue Share by Type (2021-2032)
  6. 10.4 China Brain Disease Modalities And Software Revenue by Application (2021-2032)
  7. 10.4.1 China Brain Disease Modalities And Software Revenue by Application (2021-2026)
  8. 10.4.2 China Brain Disease Modalities And Software Revenue by Application (2027-2032)
  9. 10.5 China Brain Disease Modalities And Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Brain Disease Modalities And Software Revenue (2021-2032)
  2. 11.2 Asia Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 11.2.1 Asia Brain Disease Modalities And Software Revenue by Type (2021-2026)
  4. 11.2.2 Asia Brain Disease Modalities And Software Revenue by Type (2027-2032)
  5. 11.3 Asia Brain Disease Modalities And Software Revenue Share by Type (2021-2032)
  6. 11.4 Asia Brain Disease Modalities And Software Revenue by Application (2021-2032)
  7. 11.4.1 Asia Brain Disease Modalities And Software Revenue by Application (2021-2026)
  8. 11.4.2 Asia Brain Disease Modalities And Software Revenue by Application (2027-2032)
  9. 11.5 Asia Brain Disease Modalities And Software Revenue Share by Application (2021-2032)
  10. 11.6 Asia Brain Disease Modalities And Software Revenue by Country
  11. 11.6.1 Asia Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Brain Disease Modalities And Software Revenue by Country (2021-2026)
  13. 11.6.3 Asia Brain Disease Modalities And Software Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Brain Disease Modalities And Software Revenue (2021-2032)
  2. 12.2 SAMEA Brain Disease Modalities And Software Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Brain Disease Modalities And Software Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Brain Disease Modalities And Software Revenue by Type (2027-2032)
  5. 12.3 SAMEA Brain Disease Modalities And Software Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Brain Disease Modalities And Software Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Brain Disease Modalities And Software Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Brain Disease Modalities And Software Revenue by Application (2027-2032)
  9. 12.5 SAMEA Brain Disease Modalities And Software Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Brain Disease Modalities And Software Revenue by Country
  11. 12.6.1 SAMEA Brain Disease Modalities And Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Brain Disease Modalities And Software Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Brain Disease Modalities And Software Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst